Healthcare provider profile · identity verified

Marlen Luna, MD

Family Practice · LOS ANGELES, CA · NPI 1962677831

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	506	187
Lisinopril	Lisinopril	219	82
Amlodipine Besylate	Amlodipine Besylate	192	76
Rosuvastatin Calcium	Rosuvastatin Calcium	169	71
Losartan Potassium	Losartan Potassium	163	61
Metformin Hcl	Metformin Hcl	156	62
Omeprazole	Omeprazole	132	59
Levothyroxine Sodium	Levothyroxine Sodium	123	47
Atenolol	Atenolol	104	37
Metformin Hcl Er	Metformin Hcl	88	33
Hydrochlorothiazide	Hydrochlorothiazide	82	30
Simvastatin	Simvastatin	80	28
Alendronate Sodium	Alendronate Sodium	76	35
Glipizide Er	Glipizide	70	26
Glipizide	Glipizide	69	27
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	64	26
Meloxicam	Meloxicam	64	29
Tamsulosin Hcl	Tamsulosin Hcl	62	27
Gabapentin	Gabapentin	59	29
Glipizide-Metformin	Glipizide/Metformin Hcl	59	19
Metoprolol Tartrate	Metoprolol Tartrate	54	19
Ibuprofen	Ibuprofen	53	30
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	51	18
Albuterol Sulfate Hfa	Albuterol Sulfate	48	31
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	38	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	38	13
Trazodone Hcl	Trazodone Hcl	37	13
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	36	36
Humulin N	Insulin Nph Human Isophane	33	17
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	33	11
Pradaxa	Dabigatran Etexilate Mesylate	33	13
Metoprolol Succinate	Metoprolol Succinate	32	11
Furosemide	Furosemide	29	15
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	29	12
Allopurinol	Allopurinol	28	suppressed
Famotidine	Famotidine	28	14
Bisoprolol Fumarate	Bisoprolol Fumarate	25	suppressed
Hydrocortisone	Hydrocortisone	24	16
Propranolol Hcl	Propranolol Hcl	24	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	24	suppressed
Finasteride	Finasteride	22	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	22	suppressed
Jardiance	Empagliflozin	22	11
Gavilyte-C	Peg3350/Sod Sulf,bicarb,cl/Kcl	21	21
Humulin N Kwikpen	Insulin Nph Human Isophane	19	suppressed
Spironolactone	Spironolactone	19	suppressed
Terazosin Hcl	Terazosin Hcl	19	suppressed
Sertraline Hcl	Sertraline Hcl	18	suppressed
Potassium Chloride	Potassium Chloride	17	suppressed
Trospium Chloride	Trospium Chloride	16	suppressed
Clonazepam	Clonazepam	15	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	15	suppressed
Lorazepam	Lorazepam	15	suppressed
Neomycin-Polymyxin-Dexameth	Neomycin/Polymyxin B/Dexametha	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	15	suppressed
Victoza 2-Pak	Liraglutide	15	suppressed
Alprazolam	Alprazolam	14	suppressed
Chlorthalidone	Chlorthalidone	14	suppressed
Duloxetine Hcl	Duloxetine Hcl	14	suppressed
Montelukast Sodium	Montelukast Sodium	14	suppressed
Prednisone	Prednisone	14	12
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	13	13
Carvedilol	Carvedilol	13	suppressed
Topiramate	Topiramate	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	12
Benazepril Hcl	Benazepril Hcl	12	suppressed
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Clopidogrel	Clopidogrel Bisulfate	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Spiriva Respimat	Tiotropium Bromide	12	suppressed
Temazepam	Temazepam	12	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	12	suppressed
Estradiol	Estradiol	11	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error